Eye - subfoveal choroidal neovascularisation

The PBS subsidises aflibercept, brolucizumab, faricimab and ranibizumab for patients with subfoveal choroidal neovascularisation.

Please note: You’ll get an immediate assessment when you request PBS authorities online.

Patient eligibility

The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with aflibercept, brolucizumab, faricimab and ranibizumab under the National Health Act 1953, section 85 for patients with subfoveal choroidal neovascularisation.

Patients must be eligible for the PBS and meet the relevant restriction criteria.

The Schedule of Pharmaceutical Benefits on the PBS website outlines the restrictions for prescribing aflibercept, brolucizumab, faricimab and ranibizumab.

Treatment specifics

To be eligible for PBS-subsidised treatment with these medicines, patients must be treated by an:

  • ophthalmologist
  • accredited ophthalmology registrar in consultation with an ophthalmologist.

Authority applications

Applying for initial treatment

Applications for initial authority approval to prescribe PBS-subsidised aflibercept, brolucizumab, faricimab or ranibizumab to treat subfoveal choroidal neovascularisation can be made either in:

All written applications must include:

Applications to move between different drugs to treat subfoveal choroidal neovascularisation will require a new initial authority application to be completed.

Applying for continuing treatment

Continuing PBS-subsidised treatment with aflibercept, faricimab or ranibizumab is Authority Required (Streamlined). You don’t need authority approval from us for the listed quantities and repeats.

Applications for continuing authority approval to prescribe PBS-subsidised brolucizumab to treat subfoveal choroidal neovascularisation can be made either:

More information

Call the PBS Complex Drugs Programs enquiry line for more information.

Page last updated: 17 June 2024.
QC 31836